title: Commentary: revised susceptibility breakpoints: fear, loathing and good science.
authors.affiliation: From *Rempex Pharmaceuticals, San Diego, California; †Institute for Clinical Pharmacodynamics, Latham, New York; and ‡JMI Laboratories, North Liberty, Iowa.
authors.forename: Michael N
authors.initials: MN
authors.lastname: Dudley
authors.forename: Paul G
authors.initials: PG
authors.lastname: Ambrose
authors.forename: Ronald N
authors.initials: RN
authors.lastname: Jones
mesh_terms: D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D016470:Bacteremia / Q000188:drug therapy*; D002443:Ceftriaxone / Q000627:therapeutic use*; D004756:Enterobacteriaceae Infections / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008297:Male
chemical_list: D000900:Anti-Bacterial Agents; D002443:Ceftriaxone